Misplaced Pages

Chlorzoxazone: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 05:18, 12 May 2024 editBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,966 edits consistent citation formatting← Previous edit Latest revision as of 00:22, 10 December 2024 edit undoCitation bot (talk | contribs)Bots5,460,414 edits Altered issue. Formatted dashes. | Use this bot. Report bugs. | Suggested by Dominic3203 | Linked from User:Marbletan/sandbox | #UCB_webform_linked 783/2664 
Line 90: Line 90:
== Further reading == == Further reading ==
{{refbegin}} {{refbegin}}
* {{cite journal | vauthors = Dong DL, Luan Y, Feng TM, Fan CL, Yue P, Sun ZJ, Gu RM, Yang BF | title = Chlorzoxazone inhibits contraction of rat thoracic aorta | journal = European Journal of Pharmacology | volume = 545 | issue = 2-3 | pages = 161–166 | date = September 2006 | pmid = 16859676 | doi = 10.1016/j.ejphar.2006.06.063 }} * {{cite journal | vauthors = Dong DL, Luan Y, Feng TM, Fan CL, Yue P, Sun ZJ, Gu RM, Yang BF | title = Chlorzoxazone inhibits contraction of rat thoracic aorta | journal = European Journal of Pharmacology | volume = 545 | issue = 2–3 | pages = 161–166 | date = September 2006 | pmid = 16859676 | doi = 10.1016/j.ejphar.2006.06.063 }}
* {{cite journal | vauthors = Park JY, Kim KA, Park PW, Ha JM | title = Effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe | journal = Journal of Clinical Pharmacology | volume = 46 | issue = 1 | pages = 109–114 | date = January 2006 | pmid = 16397290 | doi = 10.1177/0091270005282635 | s2cid = 20092326 }} * {{cite journal | vauthors = Park JY, Kim KA, Park PW, Ha JM | title = Effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe | journal = Journal of Clinical Pharmacology | volume = 46 | issue = 1 | pages = 109–114 | date = January 2006 | pmid = 16397290 | doi = 10.1177/0091270005282635 | s2cid = 20092326 }}
* {{cite journal | vauthors = Wan J, Ernstgård L, Song BJ, Shoaf SE | title = Chlorzoxazone metabolism is increased in fasted Sprague-Dawley rats | journal = The Journal of Pharmacy and Pharmacology | volume = 58 | issue = 1 | pages = 51–61 | date = January 2006 | pmid = 16393464 | pmc = 1388188 | doi = 10.1211/jpp.58.1.0007 }} * {{cite journal | vauthors = Wan J, Ernstgård L, Song BJ, Shoaf SE | title = Chlorzoxazone metabolism is increased in fasted Sprague-Dawley rats | journal = The Journal of Pharmacy and Pharmacology | volume = 58 | issue = 1 | pages = 51–61 | date = January 2006 | pmid = 16393464 | pmc = 1388188 | doi = 10.1211/jpp.58.1.0007 }}

Latest revision as of 00:22, 10 December 2024

Muscle relaxant

Pharmaceutical compound
Chlorzoxazone
Clinical data
Trade namesLorzone, Paraflex, Muscol
AHFS/Drugs.comMonograph
MedlinePlusa682577
License data
Routes of
administration		By mouth
Drug classSkeletal muscle relaxants
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityWell absorbed
Protein binding13–18%
MetabolismHepatic
Elimination half-life1.1 hours
Duration of action3–4 hours
Excretionurine (<1%)
Identifiers
IUPAC name
  • 5-chloro-3H-benzooxazol-2-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.002.186 Edit this at Wikidata
Chemical and physical data
FormulaC7H4ClNO2
Molar mass169.56 g·mol
3D model (JSmol)
SMILES
  • Clc2cc1c(OC(=O)N1)cc2
InChI
  • InChI=1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)
  • Key:TZFWDZFKRBELIQ-UHFFFAOYSA-N
  (verify)

Chlorzoxazone (INN) is a centrally acting muscle relaxant used to treat muscle spasm and the resulting pain or discomfort. It can also be administered for acute pain in general and for tension headache (muscle contraction headache). It acts on the spinal cord by depressing reflexes. It is sold under the brand names Lorzone, Paraflex and Muscol and in combination form as Parafon Forte, a combination of chlorzoxazone and acetaminophen (paracetamol). Possible side effects include dizziness, lightheadedness, malaise, nausea, vomiting. In rare cases, chlorzoxazone may cause severe liver dysfunction. On the other hand, chlorzoxazone may reduce the liver toxicity of acetaminophen by competitive inhibition.

It is available as a generic medication.

Like metaxalone, its mechanism of action is still in question. It is believed that metaxalone works by altering serotonin levels and acting as a mild MAO inhibitor. The mechanism of action of chlorzoxazone is thought to act on GABAA and GABAB receptors and voltage-gated calcium channels to a degree. General central nervous system depression is the only currently accepted aspect to its medical benefits. Elucidation of the exact mechanism of action is ongoing but there is limited study due to the existence of more effective, safe muscle relaxants (e.g., diazepam, cyclobenzaprine, tizanidine), greatly limiting the potential benefit of identifying novel compounds which share chlorzoxazone's mechanism of action.

See also

References

  1. "Parafon DSC- chlorzoxazone tablet". DailyMed. 9 February 2010. Retrieved 5 November 2020.
  2. "Lorzone- chlorzoxazone tablet". DailyMed. 21 June 2019. Retrieved 5 November 2020.
  3. "Chlorzoxazone". LiverTox. National Institute of Diabetes and Digestive and Kidney Diseases. 2017-01-30. PMID 31643467. Retrieved 2024-05-10.
  4. Pingili RB, Vemulapalli S, Gadamsetty MV, Presingu D, Katuri R, Rachamsetty V, et al. (2023-04-17). "Chlorzoxazone reduced the paracetamol-induced toxicity via competitive inhibition of CYP2E1-mediated metabolism". Future Journal of Pharmaceutical Sciences. 9 (1). doi:10.1186/s43094-023-00484-2. ISSN 2314-7253.
  5. "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.

Further reading

External links

Skeletal muscle relaxants (M03)
Peripherally acting
(primarily antinicotinic,
NMJ block)
Non-depolarizing
Curare alkaloids
4° ammonium agents
Depolarizing
ACh release inhibitors
Centrally acting
Carbamic acid esters
Benzodiazepines
Nonbenzodiazepines
Thienodiazepines
Quinazolines
Anticholinergics
(Antimuscarinics)
Other
Directly acting
Ion channel modulators
Calcium
VDCCsTooltip Voltage-dependent calcium channels
Blockers
Activators
Potassium
VGKCsTooltip Voltage-gated potassium channels
Blockers
Activators
IRKsTooltip Inwardly rectifying potassium channel
Blockers
Activators
KCaTooltip Calcium-activated potassium channel
Blockers
Activators
K2PsTooltip Tandem pore domain potassium channel
Blockers
Activators
Sodium
VGSCsTooltip Voltage-gated sodium channels
Blockers
Activators
ENaCTooltip Epithelial sodium channel
Blockers
Activators
ASICsTooltip Acid-sensing ion channel
Blockers
Chloride
CaCCsTooltip Calcium-activated chloride channel
Blockers
Activators
CFTRTooltip Cystic fibrosis transmembrane conductance regulator
Blockers
Activators
Unsorted
Blockers
Others
TRPsTooltip Transient receptor potential channels
LGICsTooltip Ligand gated ion channels
See also: Receptor/signaling modulators • Transient receptor potential channel modulators
Portal:
Stub icon

This drug article relating to the musculoskeletal system is a stub. You can help Misplaced Pages by expanding it.

Categories:
Chlorzoxazone: Difference between revisions Add topic